References
- Diasio R B, Harris B E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989; 16: 215–237
- Daher G C, Harris B E, Diasio R B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 1990; 48: 189–222
- Wasternack C. Degradation of pyrimidines and pyrimidine analogs—Pathways and mutual influences. Pharmacol Ther 1980; 8: 629–651
- Bonadonna G, Valagussa B S. Systemic therapy in resectable breast cancer. Hematol Clin North Am 1989; 3: 727–742
- Tuchman M, Stoeckeler J S, Kiang D T. Familial pyrimidi-nemia and pyrimidinuria associated with severe flourouracil toxicity. N Engl J Med 1985; 313: 245–249
- Diasio R B, Beavers T L, Carpenter J T. Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47–51
- Harris B E, Carpenter J T, Diasio R B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome. Cancer 1991, in press